


Gene Solutions and AMPATH launch advanced genomics laboratory in Hyderabad

02 October 2025 | News

To expand access to precision medicine in India



Gene Solutions, a leading genetic testing innovator in Asia, has partnered with AMPATH (American Institute of Pathology and Laboratory Sciences), a trusted provider of high-quality diagnostic services in India, to open a new advanced genomics laboratory in Hyderabad.

This collaboration aims to bring high-value, next-generation sequencing (NGS) technologies closer to patients and healthcare providers across the country.

By combining AMPATH's extensive diagnostic network with Gene Solutions' expertise in genomics, the partnership will enable more timely, accessible, and informative testing in key areas such as reproductive health, cancer screening, and personalised medicine.

The newly established NGS laboratory in Hyderabad will offer:

- triSure NIPT – A comprehensive non-invasive prenatal screening solution that provides insights into chromosomal conditions, microdeletions, and select single-gene disorders, supporting expectant parents with safe, early options for fetal health assessment and maternal well-being.

- SPOT-MAS – An innovative, clinically validated early cancer screening solution, designed to detect signals from 75 cancer types and subtypes using a single blood sample—providing physicians with additional tools to support early intervention.
- K-TRACK, K-4CARE – World-class cancer monitoring & genomic profiling solutions powered by multi-omics, enabling physicians to personalize treatment and monitor recurrence with greater confidence.

"This partnership reflects a shared vision—making high-quality, science-driven genetic testing more widely available," said Dr Nguyen Hoai Nghia, Co-founder and CEO of Gene Solutions. "We believe that technology should be inclusive. Working with AMPATH allows us to deliver advanced solutions through a familiar and trusted healthcare network."

Dr Maneesh Bagai, COO of AMPATH shared, "We are thrilled to expand into next-generation sequencing through this strategic alliance. Together, we are redefining what's possible in diagnostics—whether it's in maternal health, early cancer detection, or personalized oncology with patient centric approach."